We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations.
- Authors
Tabori, Uri; Baskin, Berivan; Shago, Mary; Alon, Noa; Taylor, Michael D; Ray, Peter N; Bouffet, Eric; Malkin, David; Hawkins, Cynthia
- Abstract
Medulloblastoma is the prototype of treatment success in modern pediatric neuro-oncology. Unfortunately, 20% to 30% of tumors recur despite maximal resection and multimodal therapy. Multiple biologic prognostic markers have been investigated to predict recurrences, but controversy remains regarding their clinical utility. Because p53 immunopositivity is an adverse prognostic marker in pediatric medulloblastoma and TP53 mutations are associated with chemotherapy and radiation therapy resistance, we aimed to determine the extent and role of TP53 mutations in pediatric medulloblastoma treatment failure.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 8, p1345
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.23.5952